TXG Key Statistics, Chart & Performance
The current stock price of TXG is 18.75 USD. In the past month the price increased by 45.35%. In the past year, price increased by 17.92%.
TXG Latest News, Press Relases and Analysis
TXG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.48 | 224.02B | ||
| DHR | DANAHER CORP | 29.63 | 163.59B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 189.06 | 57.37B | ||
| A | AGILENT TECHNOLOGIES INC | 27.66 | 43.76B | ||
| IQV | IQVIA HOLDINGS INC | 19.93 | 39.41B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.53 | 30.62B | ||
| WAT | WATERS CORP | 32.06 | 24.23B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.2 | 19.93B | ||
| ILMN | ILLUMINA INC | 29.77 | 19.95B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.42 | 17.09B | ||
| TEM | TEMPUS AI INC | N/A | 13.41B | ||
| RVTY | REVVITY INC | 21.85 | 12.15B |
Related stock screener links
About TXG
Company Profile
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,306 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Company Info
10X GENOMICS INC-CLASS A
6230 Stoneridge Mall Road
Pleasanton CALIFORNIA 94588 US
CEO: Serge Saxonov
Employees: 1306
Phone: 19254017300
10X GENOMICS INC-CLASS A / TXG FAQ
Can you describe the business of 10X GENOMICS INC-CLASS A?
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,306 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
What is the current price of TXG stock?
The current stock price of TXG is 18.75 USD. The price decreased by -1.68% in the last trading session.
What is the dividend status of 10X GENOMICS INC-CLASS A?
TXG does not pay a dividend.
What is the ChartMill rating of 10X GENOMICS INC-CLASS A stock?
TXG has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How many employees does 10X GENOMICS INC-CLASS A have?
10X GENOMICS INC-CLASS A (TXG) currently has 1306 employees.
When does 10X GENOMICS INC-CLASS A (TXG) report earnings?
10X GENOMICS INC-CLASS A (TXG) will report earnings on 2026-01-12, after the market close.
Can you provide the short interest for TXG stock?
The outstanding short interest for 10X GENOMICS INC-CLASS A (TXG) is 13.38% of its float.
TXG Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TXG. When comparing the yearly performance of all stocks, TXG is one of the better performing stocks in the market, outperforming 88.09% of all stocks.
TXG Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TXG. While TXG has a great health rating, there are worries on its profitability.
TXG Financial Highlights
Over the last trailing twelve months TXG reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 54.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.43% | ||
| ROE | -9.72% | ||
| Debt/Equity | 0 |
TXG Forecast & Estimates
23 analysts have analysed TXG and the average price target is 16.66 USD. This implies a price decrease of -11.15% is expected in the next year compared to the current price of 18.75.
For the next year, analysts expect an EPS growth of 59.72% and a revenue growth 1.98% for TXG